Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cell Physiol. 2012 Sep;227(9):3178-84. doi: 10.1002/jcp.24065.

PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Author information

  • 1Drug Discovery Department, Moffitt Cancer Center, Tampa, Florida 33612, USA. kiran.mahajan@moffitt.org

Abstract

AKT/PKB serine threonine kinase, a critical signaling molecule promoting cell growth and survival pathways, is frequently dysregulated in many cancers. Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions. While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli. A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often associated with malignancy. Consequently, evaluating the use of small molecular inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing especially in patients treated with PI3K inhibitors.

Copyright © 2012 Wiley Periodicals, Inc.

PMID:
22307544
[PubMed - indexed for MEDLINE]
PMCID:
PMC3358464
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk